← Back
$AXSM All transactions

Axsome Therapeutics, Inc.

▼ SELL 10b5-1 Plan

$ Value

$1.1M

Shares

9,127

Price

$125

Filed

Sep 5

Insider

Name

Saad Mark E

Title

CIK

0001295913

Roles

Director

Transaction Details

Transaction Date

2025-09-05

Code

S

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

10,002

Footnotes

Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur within the next two months. | Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed. | Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options. | Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $125.00 and $125.22. | Represents additional shares held indirectly by the Reporting Person prior to September 5, 2025 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.

Filing Info

Accession No.

0000950170-25-113311

Form Type

4

Issuer CIK

0001579428

Saad Mark E's History

Date Ticker Type Value
2025-12-31 AXSM M $50K
2025-12-31 AXSM $1.0M
2025-12-31 AXSM M $155K
2025-12-31 AXSM $5.2M
2025-12-31 AXSM M $0
2025-12-31 AXSM M $0
2025-09-05 AXSM M $82K
2025-09-05 AXSM $1.1M
2025-09-05 AXSM M $0
2025-06-06 AXSM A $0

Other Insiders at AXSM (90d)

Insider Bought Sold Last
TABUTEAU HERRIOT
Chief Executive Officer
$6.0M 2026-04-21
Coleman Mark $4.0M 2026-02-26
Pizzie Nick
Chief Financial Officer
2026-04-21
Jacobson Mark L.
Chief Operating Officer
$5.7M 2026-04-21
Murdock Hunter R.
General Counsel
2026-04-21
Maizel Ari
Chief Commercial Officer
$1.4M 2026-04-22